乙型肝炎肝硬化的分期及治疗进展

孙亚朦; 尤红

doi:10.3969/j.issn.1001-5256.2016.06.003

乙型肝炎肝硬化的分期及治疗进展

DOI: 10.3969/j.issn.1001-5256.2016.06.003

孙亚朦,
尤红

首都医科大学附属北京友谊医院肝病中心国家消化系统疾病临床医学研究中心

详细信息

中图分类号: R575;R512.62
计量
- 文章访问数: 2787
- HTML全文浏览量: 34
- PDF下载量: 727
- 被引次数: 0
出版历程
- 出版日期: 2016-06-20

Advances in staging and treatment of hepatitis B cirrhosis

摘要

摘要: 肝硬化是慢性乙型肝炎疾病进展的重要阶段,明确肝硬化严重程度对评估预后至关重要,目前以肝硬化并发症为基础的临床分期应用广泛,而病理分期仍有待细化。治疗方面,2015年各肝病学会相继更新了慢性乙型肝炎诊疗指南,乙型肝炎肝硬化的抗病毒治疗较前更加积极。预后方面,有效的抗病毒治疗实现了早期肝硬化的逆转,降低了肝病相关终点事件的发生,但逆转的机制仍有待进一步探讨。
- 肝炎,乙型,慢性 /
- 肝硬化 /
- 治疗 /
- 预后 /
- 述评
Abstract: Liver cirrhosis is an important stage of the progression of chronic hepatitis B,and it is of great significance to clarify the severity of liver cirrhosis in evaluating prognosis.At present,the clinical staging based on the complications of liver cirrhosis is widely used,but pathological staging still needs to be refined.In the aspect of treatment,liver disease associations updated the guidelines for the diagnosis and treatment of chronic hepatitis B in 2015,and the antiviral therapy for hepatitis B cirrhosis has become more active.As for the prognosis,effective antiviral treatment realizes the reversion of early cirrhosis and reduces the incidence of liver- related complications,but the mechanism of reversion awaits further investigation.
- hepatitis B /
- chronic /
- liver cirrhosis /
- therapy /
- prognosis

HTML全文

参考文献(33)

[1]European Association for The Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.

[2]KAMATH PS,WIESNER RH,MALINCHOC M,et al.A model to predict survival in patients with end-stage liver disease[J].Hepatology,2001,33(2):464-470.

[3]DURAND F,VALLA D.Assessment of the prognosis of cirrhosis:Child-Pugh versus MELD[J].J Hepatol,2005,42 Suppl(1):s100-s107.

[4] KIM HJ,LEE HW.Important predictor of mortality in patients with end-stage liver disease[J].Clin Mol Hepatol,2013,19(2):105-115.

[5]D'AMICO G,GARCIA-TSAO G,PAGLIARO L.Natural history and prognostic indicators of survival in cirrhosis:A systematic review of 118 studies[J].J Hepatol,2006,44(1):217-231.

[6]ARVANITI V,D'AMICO G,FEDE G,et al.Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis[J].Gastroenterology,2010,139(4):1246-1256.

[7]FEDE G,D'AMICO G,ARVANITI V,et al.Renal failure and cirrhosis:A systematic review of mortality and prognosis[J].J Hepatol,2012,56(4):810-818.

[8] KNODELL RG,ISHAK KG,BLACK WC,et al.Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis[J].Hepatology,1981,1(5):431-435.

[9]BEDOSSA P,POYNARD T.An algorithm for the grading of activity in chronic hepatitis C.The METAVIR Cooperative Study Group[J].Hepatology,1996,24(2):289-293.

[10]ISHAK K,BAPTISTA A,BIANCHI L,et al.Histological grading and staging of chronic hepatitis[J].J Hepatol,1995,22(6):696-699.

[11]KIM MY,CHO MY,BAIK SK,et al.Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension[J].J Hepatol,2011,55(5):1004-1009.

[12]KIM SU,OH HJ,WANLESS IR,et al.The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis[J].J Hepatol,2012,57(3):556-563.

[13]BEDOSSA P.Reversibility of hepatitis B virus cirrhosis after therapy:who and why?[J].Liver Int,2015,35(Suppl 1):78-81.

[14]XU S,WANG Y,TAI DC,et al.q Fibrosis:a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients[J].JHepatol,2014,61(2):260-269.

[15] WANG Y,HOU JL.Fibrosis assessment:impact on current management of chronic liver disease and application of quantitative invasive tools[J].Hepatol Int,2016,10(3):448-461.

[16]Chinese Society of Hepatology and Chinese Society of Infectious Diseases Chinese,Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.

[17]TERRAULT NA,BZOWEJ NH,CHANG KM,et al.AASLD guidelines for treatment of chronic hepatitis B[J].Hepatology,2016,63(1):261-283.

[18] Chinese Society of Hepatology and Chinese Society of Infectious Disease,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2010,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2010,27(1):Ⅰ-ⅩⅥ.

[19]LOK AS,Mc MAHON BJ.Chronic hepatitis B:update 2009[J].Hepatology,2009,50(3):661-662.

[20] SARIN SK,KUMAR M,LAU GK,et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update[J].Hepatol Int,2016,10(1):1-98.

[21] World Health Organization.Guidelines for the screening,care and treatment of persons with hepatitis B infection[R].Geneva:World Health Organization,2015.

[22]SINN DH,LEE J,GOO J,et al.Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load[J].Hepatology,2015,62(3):694-701.

[23]DIENSTAG JL,GOLDIN RD,HEATHCOTE EJ,et al.Histological outcome during long-term lamivudine therapy[J].Gastroenterology,2003,124(1):105-117.

[24]RIZZETTO M,TASSOPOULOS NC,GOLDIN RD,et al.Extended lamivudine treatment in patients with HBe Ag-negative chronic hepatitis B[J].J Hepatol,2005,42(2):173-179.

[25]HADZIYANNIS SJ,TASSOPOULOS NC,HEATHCOTE EJ,et al.Long-term therapy with adefovir dipivoxil for HBe Ag-negative chronic hepatitis B for up to 5 years[J].Gastroenterology,2006,131(6):1743-1751.

[26]CHANG TT,LIAW YF,WU SS,et al.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J].Hepatology,2010,52(3):886-893.

[27]MARCELLIN P,GANE E,BUTI M,et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label follow-up study[J].Lancet,2013,381(9865):468-475.

[28]LIAW YF.Reversal of cirrhosis:an achievable goal of hepatitis B antiviral therapy[J].J Hepatol,2013,59(4):880-881.

[29] LOK AS.Hepatitis:Long-term therapy of chronic hepatitis B reverses cirrhosis[J].Nat Rev Gastroenterol Hepatol,2013,10(4):199-200.

[30] LIAW YF,SUNG JJ,CHOW WC,et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease[J].N Engl JMed,2004,351(15):1521-1531.

[31]PENG CY,CHIEN RN,LIAW YF.Hepatitis B virus-related decompensated liver cirrhosis:benefits of antiviral therapy[J].J Hepatol,2012,57(2):442-450.

[32]JANG JW,CHOI JY,KIM YS,et al.Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis[J].Hepatology,2015,61(6):1809-1820.

[33]PAPATHEODORIDIS GV,CHAN HL,HANSEN BE,et al.Risk of hepatocellular carcinoma in chronic hepatitis B:assessment and modification with current antiviral therapy[J].J Hepatol,2015,62(4):956-967.

施引文献

资源附件(0)

访问统计